Keyphrases
Phase I Study
100%
Selinexor
100%
Relapsed or Refractory multiple Myeloma
100%
Carfilzomib
100%
Maximum Tolerated Dose
60%
Overall Response Rate
40%
Adverse Events
20%
Anemia
20%
Overall Survival
20%
Lymphopenia
20%
Prior Exposure
20%
Dose Level
20%
Neutropenia
20%
Thrombocytopenia
20%
Long-term Efficacy
20%
Diarrhea
20%
Progression-free Survival
20%
Nausea
20%
Median Progression-free Survival
20%
Median Overall Survival
20%
Nonhematologic
20%
Nave
20%
Refractoriness
20%
Chimeric Antigen Receptor T-cell Therapy
20%
Anorexia
20%
Bridging Strategy
20%
Hematological Adverse Events
20%
Triple-class Exposed
20%
Pharmacology, Toxicology and Pharmaceutical Science
Dexamethasone
100%
Multiple Myeloma
100%
Selinexor
100%
Carfilzomib
100%
Maximum Tolerated Dose
60%
Adverse Event
40%
Overall Survival
40%
Progression Free Survival
40%
Anemia
20%
Immunotherapy
20%
Lymphocytopenia
20%
Thrombocytopenia
20%
Neutropenia
20%
Nausea
20%
Diarrhea
20%
Chimeric Antigen Receptor
20%
Anorexia
20%
Diseases
20%
Medicine and Dentistry
Dexamethasone
100%
Multiple Myeloma
100%
Selinexor
100%
Carfilzomib
100%
Adverse Event
40%
Progression Free Survival
40%
Overall Survival
40%
Anemia
20%
Immunotherapy
20%
Lymphocytopenia
20%
Neutropenia
20%
Thrombocytopenia
20%
Diarrhea
20%
Nausea
20%
Chimeric Antigen Receptor T-Cell Immunotherapy
20%
Anorexia
20%
Diseases
20%